

Ottawa Hull K1A 0C9

(21)	(A1)	2,133,421
(86)		1993/04/02
(43)		1993/10/14

5  
(51) Int.Cl. B01J 13/06; A61K 9/127; A01N 25/04

(19) (CA) APPLICATION FOR CANADIAN PATENT (12)

(54) Process for the Preparation of Microcapsules or  
Liposomes of Controlled Sizes

(72) Roux, Didier - France ;  
Diat, Olivier - France ;  
Laversanne, René - France ;

(71) Centre National de la Recherche Scientifique (C.N.R.S.)  
- France ;

(30) (FR) 92/04108 1992/04/03

(57) 12 Claims

6,021,7/89

Notice: This application is as filed and may therefore contain an  
incomplete specification.



PROCESS FOR THE PREPARATION OF MICROCAPSULES OR LIPOSOMES  
OF CONTROLLED SIZES

5 The subject of the present invention is a process for the preparation of microcapsules or liposomes of controlled size by application of a shearing having a constant shear rate to a lamellar phase.

10 Microcapsule is understood to mean a particle of micron size (0.1 to 10  $\mu\text{m}$ ), closed by one or a number of double layers (constituting the membrane) composed of at least one type of surface-active agent (molecule composed of a lipophile part and another hydrophile part which settles at interfaces). This or these membrane(s) enclose(s) in the space a volume of solvent, isolated 15 from the remainder of the solution, which is the encapsulated volume. The encapsulation yield is defined as the percentage of encapsulated volume with respect to the total volume of solvent.

20 In the specific case of surface-active agents of lipid origins, especially phospholipids, these capsules are known as liposomes.

25 Many methods for the preparation of microcapsules and liposomes have been described in the literature. The methods proposed include especially methods based on the mechanical dispersion of the surface-active agent(s) in a solvent, methods for the preparation of emulsions of a volatile organic solvent in an aqueous solvent and then evaporation of the organic part, and methods by polymerization of a monomer such as acrylic acid (for example, BE-A-808,034, FR-A-2,504,408, US-A-3,242,051 or US-A-30 4,637,905).

30 In the case of liposomes, the processes described generally contain methods by emulsification (for example, FR-A-2,315,991, FR-A-2,399,242 and FR-A-2,521,565).

35 These methods lead, in the best cases, to encapsulation levels of the order of 50 % and to relatively polydispersed particles.

The present invention proposes a simple method for the preparation of very concentrated monodispersed

than 90 %), while controlling very precisely the size of the microcapsules.

This result is obtained by subjecting a single-phase, liquid crystal, lamellar phase to a shearing having a 5 constant shear rate which is homogeneous in space.

This result is astonishing because those skilled in the art would have logically thought that the application of a shearing having a constant shear rate to a lamellar phase would have led to an at least partial orientation of this phase 10 rather than to the manufacture of small isotropic particles of given size.

The subject of the invention is therefore a process for the preparation of microcapsules of controlled sizes, in which a homogeneous, liquid crystal, 15 lamellar phase is prepared comprising at least one surface-active agent and at least one solvent and, if appropriate, a substance intended to be encapsulated, characterized in that this lamellar phase is subjected to a shearing having a constant shear rate.

20 In a first stage, a homogeneous lamellar phase is prepared consisting of at least one type of surface-active agent (ionic or nonionic) in at least one type of solvent (especially water or a saline or alcoholic aqueous solution). A lamellar phase is defined by a 25 regular stacking of membranes separated by a solvent. This is a liquid crystal phase (smectic-A), characterized by a solid nature in the direction perpendicular to the membranes and a liquid nature in the other two directions. The concentrations are chosen according to the 30 phase diagram of the system which localizes the stability region of the lamellar phase. Generally, this lamellar phase exists in all the surface-active agents/water systems at high concentrations of surface-active agents (> 30% by weight). In certain cases, this lamellar phase 35 persists at much low r concentrations of surface-active agents (as far as less than 1-10 %).

In practice, 0.5 to 50 % by weight especially of surface-active agents with respect to the lamellar phase can be used. These surface-active agents can be both

5 ionic (derivatives of optionally alkoxylated fatty acids, sulphonates, quaternary ammonium derivatives, and the like) and nonionic (polyethers, polyalcohols, and the like) and more generally any compound which can form a lamellar phase and will be chosen according to the applications of the product prepared.

10 Moreover, it is possible to prepare systems where the membrane consists of a thin film of water surrounded by two layers of surface-active agents (reverse membranes), everything being diluted in a hydrophobic solvent.

15 In the case where the membrane consists of water (reverse membrane), the solvent is chosen from hydrophobic liquids, especially aliphatic hydrocarbons ( $C_5$  to  $C_{25}$  in particular) or aromatic hydrocarbons, which are optionally halogenated, higher alcohols ( $C_4$  to  $C_{12}$  in particular), ketones, and the like.

20 This lamellar phase, once prepared, can be easily characterized by observation, under a polarized optical microscope, of the texture, thus showing flaws characteristic of the lamellar nature (focal conics, oily streaks). In the case of the concentrated phases (> 20 %), it is also possible to characterize it using X-rays. In the case of the dilute phases, it is possible 25 to characterize the lamellar nature by neutron scattering or, in extreme cases, by light scattering.

30 In a second stage, which constitutes the main novel feature of the invention, this lamellar phase is subjected to a constant shear rate, in a suitable device. There currently mainly exist two types of devices which 35 may be suitable for this purpose.

35 A first type of device is a cell, known as a Couette cell, consisting of two concentric cylinders in constant rotation with respect to one another, where the shear rate is defined by the ratio of the relative displacement rate divided by the distance between the cylinders. Another type of device is the cell of cone / plate type where a cone, whose point is directed

plate, rotates at a constant angular velocity at a distance from the plate.

In the two devices described above, it is possible to show that the shear rate is constant throughout the cell. These cells are commonly used in commercial apparatuses, in particular rheometers, which make it possible to measure the viscoelastic properties of liquids (for example: Carrimed or Rheometrics). However, their application to the preparation of microcapsules has never been envisaged. Such apparatuses can be used for the preparation of microcapsules according to the invention.

The lamellar phase must be subjected to a constant shear rate for a certain time in order to obtain a stationary state. The kinetics of formation can be monitored by measuring, as a function of time, the torque which is applied to one of the cylinders for a prescribed rate of rotation of the other (i.e. shear rate). This is easily produced on the commercial apparatuses described above. The typical time for reaching the stationary state is of the order of a few minutes to a few hours (especially 1 min to 100 min): the higher the shear rate, the shorter the time required. The shear rate typically lies between 1 and  $1000\text{ s}^{-1}$ , especially between 2 and  $400\text{ s}^{-1}$ .

Once the shearing has stopped, a cream is recovered which consists of a dense assembly of small monodisperse spheres (spherical objects) of lamellar phases. These small spheres constitute the microcapsules whose size is a direct function of the shear rate which has been applied during the preparation. It can be shown experimentally and theoretically that the diameter varies as the inverse of the square root of the shear rate.

The size can be measured by various methods. The simplest is to withdraw a small amount of cream and to fill an optically transparent cell (1 to 10 mm Helma cell, for example). By sending a laser beam through the cell and by placing a screen on the path after the cell, a scattering ring is observed whose position directly

gives the diameter  $D$  of the microcapsules by using the conventional formula:

$$D = \lambda/n/2/\sin(\theta/2)$$

$\lambda$  being the wavelength of the light, and

$n$  being the refractive index of the medium

It is also possible to place the cream obtained

It is also possible to place the cream obtained under a polarizing microscope and to observe a homogeneous texture whose characteristic size is the diameter of the microcapsule.

It is alternatively possible to produce electron microscopy images under the same conditions as those which are used to characterize the liposomes.

15 The process according to the invention makes it possible to prepare microcapsules having sizes generally between 0.1 and 50 micrometres, more commonly between 0.8 and 8 micrometres, with less than 10 % polydispersity by radius. It is suitable particularly for the preparation  
20 of liposomes.

In the undiluted state, these microcapsules are very stable and can be stored for a very long time depending on the surface-active agent used.

The microcapsules prepared in the cream form by  
25 the process according to the invention can subsequently  
be used directly to prepare a dilute solution of micro-  
capsules by simple addition of solvent. The stability of  
the microcapsules in suspension is then identical to that  
obtained by other methods and is therefore a function of  
30 the system used.

It is possible to measure the encapsulation yield either directly on the cream, by a low-frequency conductivity method, for example, or by a conventional technique on a dilute solution of microcapsules. It is also possible to measure the encapsulation yield by incorporating a dye in the lamellar phase and by measuring, after shearing and centrifuging, the concentration of dye in the supernatant. An encapsulation of the order of 90 to 95 % is generally obtained.

The process of preparation according to the invention therefore makes it possible to obtain microcapsules of controlled and monodispersed sizes. Moreover, a very high concentration of these particles is obtained.

5 This set of properties makes it possible to easily determine the characteristic size by observation of a light-scattering ring or even by direct measurement under a phase-contrast microscope.

It is possible to explain the formation of these 10 small spheres in the following way. When the shear rate is very small (typically  $< 1 \text{ s}^{-1}$ ), the system of orientation of the lamellar phase obtained is that described by Oswald and Kléman (J. de physique lettres, 43, L-411, 1983) in the case of thermotropic smectic phases. Movement then takes place by fault slipping according to the 15 laws for the lubrication of smectic materials. As soon as a critical shear rate (of the order of  $1 \text{ s}^{-1}$ ) is exceeded, the movement imposed is too rapid to enable the dislocations to move and the system forms spherical 20 objects of constant sizes which roll against each other. The size is fixed by an equilibrium between the elastic force necessary to maintain the system at a size  $D$  and the viscous force which is exerted on each of the 25 particles by its moving neighbours. It can then be shown that:

$$D = \sqrt{\frac{4\pi(2k_c + K)}{\eta d \dot{\gamma}}}$$

30 with  $k_c$  and  $K$ , which are respectively the elastic constants of the mean and Gaussian curvatures of the membrane,

$\eta$  is the viscosity of the medium

$\dot{\gamma}$  is the shear rate.

35  $d$  is the distance between membranes in the starting lamellar phase.

Independently of the encapsulation properties described above, the cream obtained is a threshold

viscoelastic medium.

The relationship which exists between the size of the microcapsules obtained and the shear rate applied shows that it is possible to adjust the size depending on 5 the applications. This also makes it possible to modify the viscoelastic properties of the system, without changing its composition, simply by modifying the value of the shear rate. It is thus possible to prepare visco- 10 elastic fluids having different viscoelastic frequencies, the viscoelastic frequency being defined as the frequency at which the elastic and viscous moduli intersect.

In an advantageous embodiment of the invention, a monomer is incorporated in the liquid crystal lamellar phase before shearing, this monomer being in the dissolved state in one of the constituents of this lamellar 15 phase, and polymerization of the monomer is initiated after the shearing stage.

The monomer can, for example, be either dissolved 20 in the water (for example acrylamide or a derivative of acrylic acid) or dissolved in the oil (styrene, for example) or, if it has surface-active properties, dissolved in the surface-active agent membrane. It is also possible to use the monomer in the pure state in order to replace one of the constituents of the lamellar phase. 25 This is the case, for example, for the oil, which can be pure styrene, or for the surface-active agent, which can be a polymerizable surface-active agent used pure. Generally, a crosslinking agent is added which makes it possible to obtain a stable polymer gel.

30 Depending on the nature of the initiation reaction of the polymerization, it may be necessary to add a chemical initiator. It is necessary, in this case, to add it before the shearing stage, in order to ensure that it is homogeneously dissolved. It is then possible 35 to trigger the polymerization reaction by modifying an external parameter (for example, by heating or exposure to ultraviolet radiation), avoiding any initiation of the reaction during the preparation stage of the microcap-

2133421

In the same way, if it is desired to encapsulate an active principle, it must be dissolved in the lamellar phase before it is sheared.

5 This phase, containing the active principle, the monomer and the initiator, is subjected to a shear rate, by the process according to the invention, which is constant for the time necessary to obtain the stationary state. This constitutes the first stage. On conclusion of this treatment, the cream obtained is recovered.

10 In a second stage, this cream is polymerized. The polymerization can be carried out either on the pure cream or on the cream diluted in the solvent which has been used for the manufacture of the liquid crystal phase. The triggering of the polymerization reaction 15 makes it possible to obtain polymerized microcapsules. These microcapsules can then be diluted or used as is.

20 These polymerized microcapsules are characterized, inter alia, by a much greater stability than that of the unpolymerized capsules (no degradation after several months) and a significant slowing-down in escape of the active principle enclosed in the capsules.

In certain cases, these microparticles can be dispersed, both in an aqueous or in an organic solvent.

25 In another embodiment of the invention, use is made, as lamellar phase, of a phase which is capable of changing from the state of a liquid crystal lamellar phase ( $L\alpha$  phase) to a gel phase ( $L\beta$  phase) at lower temperature where the surface-active agent molecules are arranged according to a solid two-dimensional nature in 30 each membrane and, after shearing, the microcapsules are brought to a temperature below the gel/liquid phase transition temperature.

35 This phase transition is well known both in lipid systems and for synthetic surface-active agents.

The microcapsules are prepared in the liquid crystal lamellar phase (high-temperature phase) by following the process described previously. The principles of formation and the results are similar to those

microcapsules is then brought to a temperature below that of the gel/liquid transition. A concentrated cream of microcapsules solidified in the gel phase is thus obtained. These microcapsules can then be diluted in a 5 solvent. If an active principle is added during the preparation of the starting liquid crystal phase, this active principle is found in the solid capsules on conclusion of the preparation. By reheating the dilute suspension of solid capsules above the gel/liquid transition 10 temperature, this principle is then released according to kinetics related to the composition of the membrane in the liquid crystal phase.

The property of certain physical gels of reversibly changing from the liquid state to the gel state as 15 a function of temperature can also be used to make possible the manufacture of gelled microparticles. It is thus possible to prepare a liquid crystal phase with the gelling polymer in the solvent. This phase is sheared above the gelling temperature of the polymer and then, 20 after obtaining the microcapsules, cooled to below the gelling temperature. The capsules obtained can then be dispersed in a solvent. By repeating the gel/liquid transition in the reverse direction, it is thus possible to control the release of an active principle (encapsulated 25 during the preparation).

It is additionally possible to couple the process according to the invention to a conventional encapsulation process: coacervation. Coacervation usually consists, in a first stage, in preparing an emulsion of a 30 hydrophobic liquid in water. A polymer is then adsorbed

at the oil/water interface to form a polymerized shell which makes it possible to stabilize this emulsion. A hydrophobic active principle is thus encapsulated in a hydrophilic capsule by this process. Moreover, the size 5 of the microcapsules thus obtained is relatively large (10-1000  $\mu\text{m}$ ).

If the same method is applied in a second stage of the process according to the invention, it is possible to encapsulate a hydrophilic compound in a hydrophilic 10 matrix (or a hydrophobic compound in a hydrophobic capsule). Moreover, the size is well controlled and can fall below one micrometre.

It is additionally possible to use the process according to the invention to prepare solid particles. To 15 this end, the process according to the invention is used as a preparatory stage of a chemical microreactor in order to prepare, for example, solid particles of controlled size. The process will be illustrated by the preparation of monodispersed nickel particles. Two 20 methodologies are applied. If a chemical reaction consists in reacting a molecule A with a molecule B (or an array of molecules), one of the reactants can be encapsulated in the microcapsules and these capsules can be dispersed in a solvent containing the reactant B. The 25 reaction is then triggered in the capsule which is being used as container (microreactor). If this reaction consists in the production of a polymerized or solid product AB, the size of the resulting object is then controlled by the amount of reactive product in the 30 capsule, by the number of reactive sites and by the concentration of the reactant outside the capsule. It is also possible, in the case of a catalytic reaction, to encapsulate the catalyst in the capsule and to place all 35 the reactants (except for the catalyst) in the solvent which is being used as diluent. The dispersion of the capsules containing the catalyst in

2133 1

30 the solvent containing the reactants leads to the triggering of the reaction within each capsule. If solid or polymerized capsules are prepared, it is again possible thus to control the size of the resulting particles.

The process for the preparation of microcapsules according to the invention finds applications in many fields.

35 1) Paints

The process can be used at a number of levels in the preparation of paints. It is possible to encapsulate an active principle and to dilute these capsules in a paint. The release of this active principle is controlled

by the size of the capsules, optional polymerization and also specific processes such as those described above (phas transition, gels, coacervation, and the like). It is also possible to incorporate solid particles prepared 5 as described above in order to give optical or dielectric properties to paints. The active principle can be an insecticide, a fungicide or any other product requiring controlled release over time. It is also possible to mix capsules of differing natures in order to obtain a better 10 distribution over time of escape of the active principle.

2) Plant protection products

It is possible to apply the process according to the invention in the plant protection field, in order to treat plant produce. Two actions can be envisaged: on the 15 one hand, as described previously, the release of an active principle can be controlled. Moreover, due to the nature of the walls of the capsules (surface-active agents) and depending on their size, these capsules can more easily pass through the protective barrier of 20 plants. Pesticides or vitamins can thus be encapsulated.

3) Photocopying

In the field of photocopying, this process makes it possible to encapsulate dyes in the preparation of colour films. Consideration may also be given to using 25 the possibility of controlling the preparation size of the solid particles in order to prepare silver salt particles of controlled size.

4) Cosmetics

In the field of cosmetics, the process is 30 directly applicabl to th preparation of capsules enclosing an active principle. Lipids, fatty acids, nonionic surface-activ agents or sugar derivativ s can be used as surface-active ag nt. The possibility of controlled release by controlling the temperature 35 (g l/liquid transition) may prove to be particularly advantageous in using a membran which has a transition

temperature below 30/35°C. The viscoelastic properties can help in the formulation of beauty creams.

#### 5) Liquid detergents

In the field of liquid detergents, consideration 5 may be given to using the process according to the invention in order to control chemical reactions which have to take place during the washing. These microcapsules can also form part of the composition of conditioners (in particular those giving L<sub>β</sub> solid phase 10 capsules).

#### 6) Agricultural foodstuffs

In the farm-produce field, the process can be used as an alternative to polymer-based processes. It 15 will be noted that the very high encapsulation level and the precise control of the size are significant assets. The active principles to be encapsulated are flavourings or any other product requiring specific protection (sweeteners, for example).

#### 20 7) Biomedical/pharmaceutical

In the biomedical and pharmaceutical field, the process can be applied in many ways.

Encapsulation of medicinal active principles or 25 biological substances can be obtained by dissolving one or a number of active principles in the starting lamellar phase. These active principles are thus found encapsulated within the microcapsules in the proportion of the encapsulation yield.

Moreover, mention may be made, as examples, of 30 the vectorization of medicaments, the development of contrast agents for medical imaging (magnetic products for magnetic resonance imaging) or preparation of artificial blood (by using fluorinated surface-active agents). It is also possible to use this process in the preparation 35 of medical tests (for example, by using polymerization).

## 8) Hydraulic binders

The process makes it possible, for example, to prepare a delay catalyst for the rapid setting of materials such as cements, concrete, plaster and the like. By encapsulating this catalyst by the process according to the invention, it is possible to delay its effect. This makes possible the use of the material and the delayed triggering of setting due to the controlled escape of the catalyst.

10 The following examples illustrate the invention with the appended figures in which:

- Fig. 1 is a phase-contrast-microscope photograph of microcapsules obtained according to the process of the invention,
- 15 - Fig. 2 represents the measurement of the size of the microcapsules as a function of the shear rate applied according to the process of the invention, and
- Fig. 3 is a diagram corresponding to the region of formation of the microcapsules as a function of the proportion of solvent and of the shear rate.

Example 1: Ionic surface-active agent + salt water

A lamellar phase is prepared by dissolving 16.8 % of an ionic surface-active agent, dioctyl sodium sulpho-25 succinate (Aerosol OT of the company Sigma Chemical Co), in 83.2 % of salt water (12 g/l sodium chloride). This lamellar phase is then subjected to a constant shear rate of  $3 \text{ s}^{-1}$  for 30 min using a rheometer (Carrimed 50) equipped with a Couette-Mooney cell. The cream obtained 30 is decanted into a transparent 1 mm cell placed in a laser beam. The size of the scattering ring observed indicates that the liposomes obtained have a diameter of 2  $\mu\text{m}$  with a polydispersity of approximately 10 %. It is possible to observe, under a polarizing microscope, a homogeneous texture of a characteristic size of 2  $\mu\text{m}$ . It 35 is possible to dilute this cream in 12 g/l salt water and to observe, under a phase-contrast microscope, a more or less concentrated solution of microcapsules (Figure 1).

Example 2: Variation in size of the microcapsules

as a function of the shear rate.

A lamellar phase is prepared by dissolving 17 % of ionic surface-active agent (Aerosol OT of the company Sigma) in 83 % of salt water (15 g/l sodium chloride). 5 This lamellar phase is then subjected to a shear rate varying from 2 to 400  $s^{-1}$ , as in Example 1. The size of the microcapsules is measured by light scattering; the curve shown in the appended Figure 2 is obtained. The size (diameter) varies linearly as a function of the 10 inverse of the square root of the shear rate from 8  $\mu\text{m}$  to 0.8  $\mu\text{m}$ .

Example 3: Reverse membrane

A reverse lamellar phase is prepared by mixing 14.85 % of pentanol, 13.77 % of SDS (sodium dodecyl sulphate), 50.06 % of dodecane and 21.32 % of water and homogenization. After having left standing, this lamellar phase is composed of water films surrounded by surface-active agents with a thickness of 20  $\text{\AA}$  and separated by a solvent composed of dodecane and pentanol with a thickness of 90  $\text{\AA}$  (characterization obtained by measuring the Bragg peak by X-ray diffraction). This phase is subjected to a constant shear rate (between 3  $s^{-1}$  and 280  $s^{-1}$ ). At each shear rate, the size in the stationary state is measured by light scattering. A size varying 20 from  $D = 1 \mu\text{m}$  to 6  $\mu\text{m}$  as a function of the shear rate is 25 obtained.

Example 4: Nonionic surface-active agent + alcohol + pure water.

A lamellar phase composed of 16 % (by weight) of 30 surface-active agent C 12 E5 (pentaethylene glycol mono n-dodecyl ether of the company Nikkol), 4.25 % of hexanol and 79.75 % of water is prepared and then subjected to a shear rate at 2  $s^{-1}$  for 10 min. A cream composed of small sph r s having a diam ter of 2  $\mu\text{m}$  is obtained which can 35 be measured by light scatt ring by the m thod d scribed in ExAMPL 1. Variation of the sh ar rate from 1  $s^{-1}$  to 10  $s^{-1}$  mak s it possible to obtain sizes varying from 1.5 to 8  $\mu\text{m}$ .

ExAMPL 5: Ionic surface-active agent + pur

water

A very dilute phase containing DDAB (didodecyl-dimethylammonium bromide of the company Aldrich) in pure water is prepared (5 % of DDAB in 95 % of water), which 5 corresponds to a distance between membranes of 800 Å (measured by neutron scattering). This phase, subjected to a constant shear rate of  $10 \text{ s}^{-1}$  for 30 min, results in a concentrated phase of small spheres with a diameter of approximately 1  $\mu\text{m}$ .

10 Example 6: Lecithin + cholesterol + water

A mixture of 47% by weight of soya lecithin (Cernes Synthelabo), 13 % of cholesterol and 40 % of water is prepared and then subjected to a constant shear rate at  $400 \text{ s}^{-1}$  for 10 min. A phase is obtained of concentrated microcapsules with a diameter of 2  $\mu\text{m}$ . It is possible to disperse these small spheres in pure water and to observe the Brownian motion of these liposomes and their size with a phase-contrast microscope. By varying the shear rate from 300 to  $700 \text{ s}^{-1}$ , the size of the 20 liposomes can be varied from 3 to 1  $\mu\text{m}$ .

Example 7: Diagram for the formation of microcapsules

In order to determine the possibility of formation of microcapsules for a given system, it is possible 25 to draw up a directional diagram which delimits the region of existence of these microcapsules as a function of the shear rate and of other parameters which can be experimentally varied. By way of example, a system identical to Example 3 was systematically studied. The 30 region of formation of microcapsules was localized as a function of two parameters: the shear rate and the degree of dilution of the lamellar phase which determines the distance between membranes. The starting reverse lamellar phase contains: 22 % of p ntanol, 31 % of SDS and 47 % of water. This phas is diluted with a mixture of 91 % of 35 dodecane and 9 % of p ntanol. The lamellar phase is stable from 0 % of dodecane to 80 % of dodecane.

The appended Figur 3 r presents the r gion of

- - - - - the microcapsules as a function of the

fraction, by volume, of dodecane and of the shear rate. This diagram was obtained with a 2 mm Couette cell. In this figure, the region 2 where the microcapsules are formed is limited by two lines which correspond respectively to a region which is, taken as a whole, oriented with the membranes parallel to the direction of flow with faults (region 1 at low shear rate) or faultless (region 3 at high shear rate) in this direction.

10           Example 8: Preparation of polymerized micro-  
          capsules.

15           A lamellar phase is prepared containing by weight: 30 % of Aerosol OT, 60 % of salt water (15 g/l of NaCl), 9 % of acrylamide and 1 % of methylenebisacrylamide (crosslinking agent). 50  $\mu$ l of a solution of triethanolamine ( $60 \text{ g.l}^{-1}$ ) in water and 50  $\mu$ l of a solution containing  $0.2 \text{ g.l}^{-1}$  of methylene blue and  $0.2 \text{ g.l}^{-1}$  of eosine (initiator of the polymerization reaction in the presence of light) are added to 1 g of this preparation. Care is taken not to expose the mixture to light during the preparation stage of the micro-  
20           capsules. This liquid crystal phase is placed in a Couette (or cone/plate) cell and subjected to a constant shear rate of  $20 \text{ s}^{-1}$  for 2 hours. After this stage, the cream thus obtained is placed in a quartz cell and subjected to luminous radiation (sunlight or mercury vapour lamp) for a few minutes. A progressive decoloration then takes place, indicating consumption of the initiators and initiation of the reaction. A cream of  
25           polymerized microcapsules is then recovered. These microcapsules can be diluted in a salt water solution (15 g/l) and observed under an optical microscope. It is also possible to dilute these microcapsules in cyclo-  
          hexane. Small polymer capsules in suspension in a reverse phase are then obtained. Measurement by dynamic light scattering indicates that these particles have a diameter  
30           of 0.2  $\mu\text{m}$ .

35           As a variant, it is possible to dilute the cream by a factor of 2 (in salt water containing 15 g/l of NaCl) before carrying out the polymerization stage.

Similar microcapsules are then obtained.

Example 9: Preparation of polymerized microcapsules

A mixture containing 30 % of Aerosol OT, 50 % of 5 salt water (15 g/l of NaCl), 15 % of acrylamide and 5 % of methylenebisacrylamide (crosslinking agent) is prepared. 50  $\mu$ l of a solution of triethanolamine (60 g.l<sup>-1</sup>) in water and 50  $\mu$ l of a solution containing 0.2 g.l<sup>-1</sup> of 10 methylene blue and 0.2 g.l<sup>-1</sup> of eosine (initiator of the polymerization reaction in the presence of light) are 15 added to 1 g of this preparation. This phase is subjected to shearing and then to the action of ultraviolet radiation and microparticles are obtained. These microcapsules are more stable than in Example 8 and their size remains constant with time.

Example 10: Preparation of phase transition microcapsules.

A phase containing by weight 10 % of SDS (sodium dodecyl sulphate), 10 % of dodecanol and 80 % of 20 g/l salt water is prepared (an active principle, for example calcein (fluorescent agent) can be added to this water in order to demonstrate the effect indicated). This phase is sheared at a temperature of 50°C for 15 min at a shear rate of 20 s<sup>-1</sup>. The cream withdrawn is then cooled to a 25 temperature of 20°C. The capsules obtained can then be diluted in a salt water phase (20 g/l) and a suspension of solid particles with the active principle encapsulated 30 is obtained. By reheating this suspension above the gel point (approximately 40°C), the latter is released. In the case where the active principle is calcein, the release can be monitored by fluorescence with the presence of an agent which inhibits fluorescence in the water of dilution (cobalt salt, for example).

EXAMPLE 11: Preparation of colloidal nickel 35 particles of controlled size.

0.1 ml of a 10<sup>-2</sup>M solution of sodium tetrachloro-palladate is added to 1 g of a lamellar phase containing 17 % by mass of Aerosol OT and 83 % of 15 g/l salt water. This phase is sheared at 4 s<sup>-1</sup> for 2 h. 0.2 g of the

cream of small spheres obtained is dispersed in 2 ml of 15 g/l salt water and then 1 ml of a 5 % by mass solution of dimethylamineborane is added thereto. After a few minutes, 1 ml of a solution containing 0.1 mol/l of nickel(II) chloride, 0.1 mol/l of sodium gluconate, 0.2 mol/l of sodium hypophosphite and 3.8 % by volume of concentrated ammonia is added. The solution darkens immediately and gas evolution appears. The nickel particles can be collected by centrifuging. Study by X-ray diffraction indicates a size of 300  $\pm$  25 Å.

CLAIMS

1. Process for the preparation of microcapsules of controlled sizes, in which a single-phase, homogeneous, liquid crystal, lamellar phase is prepared comprising at least one surface-active agent and at least one solvent and, if appropriate, a substance intended to be encapsulated and forming a stack of membranes, characterized in that this lamellar phase is subjected to a shearing having a constant rate.
- 5 10 2. Process according to Claim 1, characterized in that the solvent is water or an aqueous saline solution.
3. Process according to Claim 1 or 2, characterized in that the microcapsules are liposomes.
- 15 4. Process according to Claim 1, characterized in that the membranes are reverse membranes formed from water surrounded by surface-active agent in a hydrophobic solvent.
- 20 5. Process according to any one of Claims 1 to 4, characterized in that the surface-active agent(s) constitute(s) from 0.5 to 50 % by weight of the lamellar phase.
- 25 6. Process according to any one of Claims 1 to 5, characterized in that the shear rate is between 1 and  $1000\text{ s}^{-1}$ .
7. Process according to Claim 6, characterized in that the shear rate is between 2 and  $400\text{ s}^{-1}$ .
- 30 8. Process according to one of Claims 1 to 7, characterized in that the constant shear rate is produced using a cell consisting of two concentric cylinders in constant rotation with respect to one another.
9. Process according to any one of Claims 1 to 7, characterized in that the constant shear rate is produced using a cell consisting of a cone/plate.
- 35 10. Process according to any one of Claims 1 to 9, characterized in that a monomer is incorporated in the liquid crystal lamellar phase before shearing, this monomer being in the dissolved state in one of the constituents of this lamellar phase, and the

polymerization of the monomer is initiated after the shearing.

11. Process according to any one of Claims 1 to 10, characterized in that use is made of a lamellar phase 5 capable of changing to the gel phase state at lower temperature and, after shearing, the microcapsules are brought to a temperature below the gel/liquid phase transition temperature.

12. Process according to any one of Claims 1 to 11, 10 characterized in that the microcapsules have a diameter of 0.1 to 10  $\mu\text{m}$ .